Recurrent Respiratory Papillomatosis (RRP) Treatment Enters a New Era, Yet Critical Unmet Needs Remain | Thelansis

Thelansis Releases Its 2026 Recurrent Respiratory Papillomatosis (RRP) Emerging Therapy, Unmet Needs, and TPP Insights Report, Mapping The Competitive Landscape Post-First Approval And What Comes Next For Patients, Physicians, And Pharma Executive Summary For most of their lives, people with recurrent respiratory